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histologic fibrosis. Advances in therapy with direct acting antivirals have led to 
improvements in treatment success. The objective of this study was to assess if 
it is now cost-effective to treat all CH-C genotype 1 patients regardless  
of histologic fibrosis stage. METHODS: A decision analytic Markov model 
simulating patients until death was used to compare two strategies for treating 
CH-C genotype 1: Triple therapy with biopsy (TT) or treat all (TTA). For TT, 
patients with moderate or advanced fibrosis were treated; others were biopsied 
every 5 years until age 70. Triple therapy consisted of telaprevir for 12 weeks, 
along with double-therapy (pegylated-interferon and ribavirin) for 24 or 48 weeks 
depending on response. The reference case was a treatment-naïve 50-year-old. 
Parameters were taken from the literature, Medicare fee schedule and  
drug acquisition cost. Effectiveness was measured in quality-adjusted life 
years(QALYs), and disease progression. Strategies were compared on the basis of 
cost, effectiveness and the incremental cost-effectiveness ratio (ICER, in $/QALY). 
Cost and effectiveness were discounted at 3% annually. RESULTS: For TT, 58% 
were treated initially and 25% were treated later. TTA led to less disease 
progression: Decompensated cirrhosis (11.8% vs. 13.4%), liver cancer (10.5% vs. 
12.0%), and liver transplant (4.6% vs. 5.2%). TTA was more expensive, $103,135 vs. 
$90,904, but more effective, 17.195 vs. 16.383 QALYs. TTA was very cost- 
effective with an incremental cost-effectiveness ratio of just $15,063/QALY. 
CONCLUSIONS: The recommendation to treat CH-C genotype 1 patients  
with moderate and advanced fibrosis, and monitor those with mild fibrosis, 
must be reassessed with increasingly more effective anti-HCV therapy.  
Treating everyone may be even more cost-effective for newer, more  
effective treatments with less side effects and shorter regimens (e.g. oral agents 
only).  
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OBJECTIVES: Current influenza vaccination practice using trivalent inactivated 
vaccine (TIV) and trivalent live attenuated influenza vaccine (LAIV) covers only 
one of two commonly circulating influenza B lineages; mismatch and co-
circulation are frequent and unpredictable. We evaluated the health outcomes 
and cost-effectiveness of universal vaccination with QIV compared with current 
vaccination practice. METHODS: We used a 1-year decision-tree from a societal 
perspective, including influenza-associated productivity losses and death. US 
Population was stratified to model age-specific (< 5, 5-17, 18-49, 50-64, and 65+) 
vaccination coverage, vaccine efficacy and risks of influenza complications. 
Rates of influenza, health care utilization, disease-related costs, and survival 
were estimated from published data where possible. Annual cases, lifetime costs 
(2011 USD) and quality adjusted life years (QALYs) lost were calculated and 
discounted (3% per annum) appropriately. We conducted one-way and 
probabilistic sensitivity analyses. RESULTS: Results suggest that vaccination 
with QIV instead of TIV/LAIV is expected to yield 77,817 fewer medically-
attended influenza cases, approximately 4,360 fewer related hospitalizations and 
868 fewer deaths per year. QIV vaccination is expected to result in approximately 
4,342 fewer QALYs lost compared with TIV/LAIV. The model projects QIV to  
be cost-effective at $50,000/QALY, excluding death-related productivity losses, 
avoiding double counting as death-related QALYs are included, at a price 
increment of 35% over the average weighted TIV price. The increase  
in vaccination costs ($385 million) is offset by a $411 million reduction in 
influenza-related treatment costs, comprising $142 million in direct medical 
costs (physician visits, antivirals, and outpatient and inpatient care) and $269 
million in direct non-medical cost savings. Results were robust in sensitivity 
analyses. CONCLUSIONS: Under the model assumptions, a strategy of 
vaccination with a quadrivalent influenza vaccine is expected to be a cost-
effective alternative to current practice, by reducing the costs as well as cases, 
hospitalizations and deaths associated with vaccine-mismatched influenza B 
disease.  
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OBJECTIVES: To adapt an existing and previously published economic (micro-
simulation model) in HIV (ARAMIS) to evaluate the cost-effectiveness of 
maraviroc (MVC) in the US in treatment naïve HIV-patients based on the MERIT 
(Maraviroc versus Efavirenz in Treatment-Naive Patients) study. METHODS: MVC 
was compared to efavirenz (EFV) in treatment naïve patients with CCR5-tropic 
HIV. Efficacy and safety data were based on the post hoc analysis in the MERIT 
study in patients rescreened with an Enhanced Sensitivity Trofile Assay (ESTA). 
ARAMIS-MVC is a microsimulation Markov model, has a lifetime analytic time 
horizon with a monthly cycle length. Health states are defined in terms of 
chronic and acute HIV/AIDS. Treatment algorithms were updated based on 
guidelines and expert opinion. Long-term non-AIDS diseases (Cardiovascular, 
hepatic and renal diseases and non-AIDS defining cancer) were included in the 
model to reflect the higher prevalence of these illnesses in the HIV population 
and depended on age, CD4-cell count and hepatic status. Costs included 
antiretroviral treatment costs, HIV care, testing, adverse event (gastrointestinal 
events, rash, neuropsychiatric adverse events) and non-AIDS disease costs, at 
the 2012 level. The cohort of the model used the population included in the 
MERIT study and 1,000,000 simulations were used for the model. RESULTS: The 
ARAMIS-MVC model indicates that MVC compared to EFV over a life time is 
associated with some additional quality-adjusted life years (QALY) (0.092 
difference) but with some additional total costs ($8,900 additional costs for MVC). 
The incremental cost effectiveness ratio for MVC compared to EFV is $96,000 per 
QALY gained. Life expectancy with MVC was slightly higher than EFV (2.7 
months difference). CONCLUSIONS: MVC is a cost-effective treatment option for 
CCR5 tropic treatment-naïve patients in the US considering a threshold of 
$100,000/QALY.  
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OBJECTIVES: Current guidelines for the treatment of acute bacterial skin and 
skin structure infections (ABSSSI) recommend treatment pathways based on the 
infection types and severity. However, few studies have attempted to establish 
the health care resource utilization and costs overall and in various treatment 
settings, e.g., ED visits, in-patient, outpatient visit and/or treatment (e.g. infusion 
center), and outpatient pharmacy, using real world data. METHODS: The medical 
and pharmacy administrative claims of adult ABSSSI subjects with continuous 
commercial or Medicare Advantage enrollment with Part D prescription drug 
coverage (MAPD) between 01 January 2009 and 31 December 2011 were extracted 
from a large national health plan affiliated with OptumInsight. Subjects were 
grouped based on their initiation of five MRSA-active antibiotics: linezolid, 
vancomycin, daptomycin, clindamycin, or tigecycline. Health care resource 
utilization and costs were assessed for each treatment group. RESULTS: After 
applying inclusion and exclusion criteria, 8,332 commercial and 4,218 MAPD were 
included in the study. The average age was 50 years for commercial enrollees 
and 69 years for MAPD enrollees. The Quan-Charlson comorbidity index varied 
among treatment groups and, a majority of the clindamycin treatment subjects 
had few or no comorbidities. The average ABSSSI-related total health care cost, 
per patient per month, was $18,290 including $7,261(39.7%) for inpatient cost, 
$825(4.5%) for ED visits, $2,447 (13.4%) for outpatient treatment/visits, 
$1233(6.7%) for pharmacy claims, $971(5.3%) for office visits, and $5553 (30.4%) 
for other medical cost. The costs overall and in various treatment settings varied 
by initial antibiotic choices and insurance plans. CONCLUSIONS: Inpatient 
treatment remains the largest component of total ABSSSI treatment cost. To 
minimize the burden on the health care system, there is an urgent need to 
develop new antibiotics that prevent or decrease the number of hospitalizations 
and reduce the length of inpatient stays.  
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OBJECTIVES: Boceprevir is indicated for the treatment of chronic hepatitis C 
virus (HCV) genotype 1 in combination with peginterferon-alpha and ribavirin 
(PEGATRON). Boceprevir plus PEGATRON has been shown to significantly 
increase sustained virologic response (SVR) rates in naive and previously treated 
adults with chronic hepatitis C (CHC) genotype 1, compared to PEGATRON 
alone.This analysis is to determine the cost-effectiveness of PEGATRON with 
boceprevir compared to PEGATRON alone in treatment-naive and treatment-
experienced patients in Australia. METHODS: A semi-Markov model was 
constructed to capture the early stages of CHC and the possibility of SVR, as well 
as important downstream health states which impact on quality of life, survival 
and resource utilisation. Early stages of liver disease were defined by levels F0 to 
F3 of METAVIR scoring system. Advanced stages were defined as compensated 
cirrhosis, decompensated cirrhosis, and primary hepatocellular carcinoma. 
Patients who moved from a baseline fibrosis score of F0-F3 to SVR were assumed 
to be free of any further disease progression, remaining in a viral-negative state 
until death. Patients who moved from a baseline fibrosis score of F4 to SVR were 
assumed to retain some risk of liver complications due to pre-existing liver 
damage. Subjects who failed to achieve SVR were assumed to be at risk of 
disease progression until death. Costs and preference-based utility values varied 
by health state, and were aggregated over the patients’ lifetimes to calculate an 
incremental cost-utility ratio. RESULTS: The base case incremental cost-utility 
ratio was AU$38,712 per additional QALY in the treatment-naïve population, and 
AU$33,750 in the treatment-experienced population. The model was robust to 
variations in the SVR rate and model duration. CONCLUSIONS: The use of 
boceprevir for untreated chronic genotype 1 HCV is a cost-effective option for 
adult patients with CHC genotype 1.  
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